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S1 Algorithm
The constrained multistate test tube design algorithm described in the present work builds on the test tube design
algorithm described by Wolfe and Pierce.1 The two algorithms were developed concurrently so that the notation
and concepts employed for sequence design over the ensemble of a single test tube would generalize naturally to
performing sequence design over the ensemble of an arbitrary number of test tubes subject to user-specified sequence
constraints. Readers interested in a detailed understanding of the present algorithm will benefit from reading the
Algorithm section of Reference 1, which contains thorough descriptions of a subset of the algorithmic ingredients
used in the present work. For conciseness, if an algorithmic ingredient requires no or minimal generalization and
there is little risk of confusion, we simply refer to Reference 1 for details (using the same section heading for clarity).
If some generalization in notation or concept is required and there is a risk of confusion, we restate the description
of Reference 1 with updated details below (again using the same section heading for clarity). If a new algorithmic
ingredient is required in the present setting, we provide full details below.
S1.1 Secondary Structure Model
The secondary structure, s, of one or more interacting nucleic acid strands is defined by a set of base pairs.2 A
polymer graph representation of a secondary structure is constructed by ordering the strands around a circle, drawing
the backbones in succession from 50 to 30 around the circumference with a nick between each strand, and drawing
straight lines connecting paired bases. A secondary structure is unpseudoknotted if there exists a strand ordering
for which the polymer graph has no crossing lines. A secondary structure is connected if no subset of the strands
is free of the others. A complex of interacting strands is specified as a strand ordering, ⇡, corresponding to the
structural ensemble, Γ, containing all connected polymer graphs with no crossing lines.1 (We dispense with our
prior convention2–4 of calling this entity an ordered complex.) See Section S1.3 of Reference 1 for a discussion
of distinguishability issues. A test tube may contain an arbitrary number of strand species interacting to form an
arbitrary number of complex species in a dilute solution.
The sequence, φ, of a complex is specified as a list of bases φa 2 {A,C,G,U} for a = 1, . . . , |φ| (T replaces U
for DNA). Each base pair in a secondary structure is a Watson–Crick pair (A·U or C·G) or a wobble pair (G·U). For
sequence φ and secondary structure s 2 Γ, the free energy,∆G(φ, s), is calculated using nearest-neighbor empirical
parameters for RNA5–7 in 1M Na+ or for DNA7,8 in user-specified concentrations of Na+ and Mg++.9, 10 These
physical models have practical utility for the analysis11–19 and design11,12, 20–49 of functional nucleic acid systems,
and provide the basis for rational analysis and design of equilibrium base-pairing in test tube ensembles for reaction
pathway engineering.
S1.2 Analyzing Equilibrium Base-Pairing in the Multistate Test Tube Ensemble
Let  0h denote the set of strand species that interact in test tube h 2 ⌦ to form the set of complex species  h. For
complex j 2  h, with sequence φj and structural ensemble Γj , the partition function
Q(φj) =
X
s2Γj
exp [−∆G(φj , s)/kBT ]
can be used to calculate the equilibrium probability of any secondary structure s 2 Γj :
p(φj , s) = exp [−∆G(φj , s)/kBT ] /Q(φj).
Here, kB is the Boltzmann constant and T is temperature. The equilibrium base-pairing properties of complex j
are characterized by the base-pairing probability matrix P (φj), with entries P a,b(φj) 2 [0, 1] corresponding to the
probability,
P a,b(φj) =
X
s2Γj
p(φj , s)S
a,b(s),
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that base pair a ·b forms at equilibrium within ensemble Γj . Here, S(s) is a structure matrix with entries Sa,b(s) = 1
if structure s contains base pair a · b and Sa,b(s) = 0 otherwise. For convenience, the structure and probability
matrices are augmented with an extra column to describe unpaired bases. The entry Sa,|s|+1(s) is unity if base a is
unpaired in structure s and zero otherwise; the entry P a,|j |+1(φj) 2 [0, 1] denotes the equilibrium probability that
base a is unpaired over ensemble Γj . Hence the row sums of the augmented S(s) and P (φj) matrices are unity.
Let Q h ⌘ Qj 8j 2  h denote the set of partition functions for the complexes in tube h. The set of equilib-
rium concentrations, xh, h , (specified as mole fractions) are the unique solution to the strictly convex optimization
problem:2
min
xh, h
X
j2 h
xh,j(log xh,j − logQj − 1) (S1a)
subject to Ai,jxh,j = x
0
h,i 8i 2  0h, (S1b)
where the constraints impose conservation of mass. A is the stoichiometry matrix with entries Ai,j corresponding to
the number of strands of type i in complex j, and x0h,i is the total concentration of strand i introduced to test tube h.
To analyze the equilibrium base-pairing properties of all test tubes h 2 ⌦, the partition function, Qj , and
equilibrium pair probability matrix, Pj , must be calculated for each complex j 2  using ⇥(|φj |3) dynamic pro-
grams.2,50–57 The equilibrium concentrations, xh, h 8h 2 ⌦, are calculated by solving a convex programming
problem using an efficient trust region method at a cost that is typically negligible by comparison.2 The overall time
complexity to analyze the test tubes in ⌦ is then O(| ||φ|3max), where |φ|max is the size of the largest complex.
Evaluation of the multistate test tube ensemble defect, M, requires calculation of the complex partition func-
tions, Q , which are used to calculate the equilibrium concentrations, xh, h 8h 2 ⌦, as well as the equilibrium pair
probability matrices, P on , which are used to calculate the complex ensemble defects, n on , and the normalized test
tube ensemble defects, M⌦. Hence, the time complexity to evaluate the design objective function over the set of
target test tubes, ⌦, is the same as the time complexity to analyze equilibrium base-pairing in ⌦.
S1.3 Test Tube Ensemble Focusing
To reduce the cost of sequence optimization, the set of complexes,  , is partitioned into two disjoint sets:
 =  active [ passive,
where  active denotes complexes that will be actively designed and  passive denotes complexes that will inherit
sequence information from active. Only the complexes in  active are directly accounted for in the focused test tube
ensembles that are used to evaluate candidate sequences. Initially, we set
 active =  on,  passive =  o↵ , (S2)
where
 on ⌘ [h2⌦ onh
is the set of complexes that appear as on-targets in at least one test tube, and
 o↵ ⌘  − on
is the set of complexes that appear as off-targets in at least one test tube and do not appear as on-targets in any test
tube. Hence, with test tube ensemble focusing, only complexes that are on-targets in at least one test tube are actively
designed at the outset of sequence design.
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S1.4 Hierarchical Ensemble Decomposition
To enable efficient estimation of test tube ensemble properties, the structural ensemble Γj of each complex j 2
 active is hierarchically decomposed into a (possibly unbalanced) binary tree of conditional subensembles, yielding
a forest of decomposition trees. Each complex j 2  active contributes a single tree to the decomposition forest
whether it is contained in one or more tubes h 2 ⌦. The structural ensemble of each parent node within the forest is
decomposed using one or more exclusive split-points to partition the parent nucleotides to its children. See Reference
1 for details on hierarchical ensemble decomposition. Let ⇤ denote the set of all nodes in the forest. Let ⇤d denote
the set of all nodes at depth d.
S1.4.1 Structure-Guided Decomposition of On-Target Complexes
At the outset of sequence design, equilibrium base-pairing probabilities are not yet available to guide ensemble
decomposition. Instead, structure-guided hierarchical ensemble decomposition is performed (using a single split-
point per parent) for each on-target complex j 2  active, yielding a forest of | on| decomposition trees. See
Reference 1 for details on structure-guided decomposition.
S1.4.2 Stop Condition Stringency
In order to build in a tolerance for a basal level of decomposition defect as subsequences are merged moving up the
decomposition forest, the stringency of the stop condition (3) is increased by a factor of fstringent 2 (0, 1) at each
level moving down the decomposition forest:
f stopd ⌘ fstop(fstringent)d−1 8d 2 {1, . . . , D}.
S1.5 Efficient Estimation of Test Tube Ensemble Properties
During sequence optimization, the design objective function is estimated based on physical quantities calculated
efficiently at any depth d 2 {1, . . . , D} in the decomposition forest.
S1.5.1 Complex Partition Function Estimate
For each complex j 2  active, the complex partition function estimate, Q˜j , is calculated from conditional partition
functions evaluated efficiently at any depth d 2 {1, . . . , D} as described in Reference 1.
S1.5.2 Complex Pair Probability Matrix Estimate
For each complex j 2  active, the complex pair probability matrix estimate, P˜j , is calculated from conditional pair
probability matrices evaluated efficiently at any depth d 2 {1, . . . , D} as described in Reference 1.
S1.5.3 Complex Concentration Estimate using Deflated Mass Constraints
For each tube h 2 ⌦, the complex concentration estimates, x˜h, activeh , are calculated using the complex partition
function estimates Q˜ activeh previously evaluated at any depth d 2 {1, . . . , D} as described in Reference 1. Deflated
mass constraints are used to model the effect of the neglected off-target complexes in  passiveh .
S1.5.4 Complex Ensemble Defect Estimate
For each complex j 2  on, the complex ensemble defect estimate, n˜j , is calculated using the complex pair probabil-
ity matrix estimate P˜j previously evaluated at any depth d 2 {1, . . . , D} as described in Reference 1. For complex
S6
j, the contribution of nucleotide a to the complex ensemble defect estimate is given by:
n˜aj = 1−
X
1b|j |+1
P˜ a,bj S
a,b
j
and the complex ensemble defect estimate is then:
n˜j =
X
1a| j |
n˜aj . (S3)
S1.5.5 Test Tube Ensemble Defect Estimate
For each tube h 2 ⌦, the test tube ensemble defect estimate based on x˜h, activeh and n˜ onh calculated at any depth
d 2 {1, . . . , D}, is:
C˜h =
X
j2 onh
c˜h,j , (S4)
where
c˜h,j = n˜j min (x˜h,j , yh,j) + |φj |max (yh,j − x˜h,j , 0) (S5)
is the contribution of complex j. The normalized test tube ensemble defect estimate for tube h 2 ⌦ at depth
d 2 {1, . . . , D} is then:
M˜h = C˜h/ynth , (S6)
where
ynth =
X
j2 onh
|φj |yh,j
is the total concentration of nucleotides in tube h.
S1.5.6 Multistate Test Tube Ensemble Defect Estimate
For the set of target test tubes⌦, the objective function estimate based on M˜⌦ evaluated at any depth d 2 {1, . . . , D}
is then:
M˜ = 1|⌦|
X
h2⌦
M˜h. (S7)
We write M˜d in subsequent equations where it is helpful note the depth d at which M˜ was calculated.
Note that equations (S3)–(S7) may be collected into the single equation:
M˜ =
X
h2⌦
X
j2 onh
X
1a| j |
M˜ah,j (S8)
where
M˜ah,j ⌘
1
|⌦|ynth
⇥
n˜aj min(x˜h,j , yh,j) + max(yh,j − x˜h,j , 0)
⇤
, (S9)
is the contribution of nucleotide a in complex j 2  onh in tube h 2 ⌦ to the multistate test tube ensemble defect
estimate, M˜, evaluated at any depth d 2 {1, . . . , D}. This representation is convenient when defining objective
function weights (Section S1.6) and when defining defect-weighted mutation sampling during leaf mutation and
defect-weighted reseeding during leaf reoptimization (Sections S1.7.2 and S1.7.3).
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S1.6 Adjusting Design Priorities using Defect Weights
The user may adjust design priorities by specifying weights for contributions to the multistate test tube ensemble
defect estimate, M˜:
• Nucleotide weight: wah,j weights the contribution of nucleotide a in complex j 2  onh in tube h 2 ⌦.
• Complex weight: wh,j weights the contribution of complex j 2  onh in tube h 2 ⌦ (equivalent to setting wah,j
for all nucleotides 1  a  |φj |).
• Test tube weight: wh weights the contribution of tube h 2 ⌦ (equivalent to setting wh,j for all complexes
j 2  onh ).
Each weight takes a value in the interval [0,1). By default, all weights are unity. Increasing the weight for a
nucleotide, complex, or test tube will lead to a corresponding increase in the allocation of effort to designing this
entity, typically leading to a corresponding reduction in the defect contribution of the entity. Likewise, decreasing
the weight for a nucleotide, complex, or test tube will lead to a corresponding decrease in the allocation of effort to
designing this entity, typically leading to a corresponding increase in the defect contribution of the entity.
Weights are incorporated into the objective function by replacing the defect contribution (S9) with the weighted
defect contribution
M˜ah,j ⌘
whwh,jw
a
h,j
|⌦|ynth
⇥
n˜aj min(x˜h,j , yh,j) + max(yh,j − x˜h,j , 0)
⇤
, (S10)
and summing using (S8) as before. If desired, the user can set weights at all three levels, leading to a multiplicative
effect. The complex weights and test tube weights exist purely for convenience, as their effects can always be
replicated by appropriately setting nucleotide weights (more tediously).
S1.7 Sequence Optimization at the Leaves of the Decomposition Forest
S1.7.1 Initialization
At the outset of sequence optimization, sequences are randomly initialized subject to the constraints inR by solving
a constraint satisfaction problem using a branch and propagate algorithm (Section S1.11.3).
S1.7.2 Leaf Mutation
To minimize computational cost, all candidate mutation sets are evaluated at the leaf nodes, k 2 ⇤D, of the decom-
position forest. Leaf mutation terminates if the leaf stop condition,
M˜D  f stopD , (S11)
is satisfied. Here, M˜D denotes the objective function estimated at level D. A candidate mutation set is accepted if
it decreases the objective function estimate (S8) and rejected otherwise.
We perform defect weighted mutation sampling by selecting nucleotide a in complex j 2  onh in tube h 2 ⌦ for
mutation with probability,
M˜ah,j/M˜D, (S12)
proportional to its contribution to the objective function. After selecting a candidate mutation position, a candidate
mutation is randomly selected from the set of permitted nucleotides at that position. If the resulting sequence is
infeasible (due to constraint violations caused by the candidate mutation), a feasible candidate sequence, φˆ⇤D , is
generated by solving a constraint satisfaction problem using a branch and propagate algorithm (Section S1.11.4).
A feasible candidate sequence, φˆ⇤D , is evaluated via calculation of the objective function estimate, M˜D, if the
candidate mutation set, ⇠, is not in the set of previously rejected mutation sets, γbad. The set, γbad, is updated after
each unsuccessful mutation and cleared after each successful mutation. The counter mbad is used to keep track of
the number of consecutive failed mutation attempts; it is incremented after each unsuccessful mutation and reset to
zero after each successful mutation. Leaf mutation terminates unsuccessfully ifmbad ≥Mbad. The outcome of leaf
mutation is the feasible sequence, φ⇤D , corresponding to the lowest encountered M˜D.
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S1.7.3 Leaf Reoptimization
After leaf mutation terminates, if the leaf stop condition (S11) is not satisfied, leaf reoptimization commences. At the
outset of each round of leaf reoptimization, we perform defect-weighted reseeding ofMreseed positions by selecting
nucleotide a for reseeding (with a new random initial sequence) with probability (S12). Following reseeding, a
feasible candidate sequence, φˆ⇤D , is generated by solving a constraint satisfaction problem using a branch and
propagate algorithm (Section S1.11.5). After a new round of leaf mutation starting from this reseeded feasible
sequence, the reoptimized candidate sequence, φˆ⇤D , is accepted if it decreases M˜D and rejected otherwise. The
counter mreopt is used to keep track of the number of rounds of leaf reoptimization; mreopt is incremented after
each rejection and reset to zero after each acceptance. Leaf reoptimization terminates successfully if the leaf stop
condition is satisfied and unsuccessfully if mreopt ≥ Mreopt. The outcome of leaf reoptimization is the feasible
sequence, φ⇤D , corresponding to the lowest encountered M˜D.
S1.8 Subsequence Merging, Redecomposition, and Reoptimization
Moving down the decomposition forest, hierarchical ensemble decomposition makes the assumption that base pairs
sandwiching parental split-points form with probability approaching unity. Conditional child ensembles enforce
these sandwiching base pairs at all levels in the decomposition forest in accordance with the decomposition assump-
tion. As subsequences are merged moving up the decomposition forest, the accuracy of the decomposition assump-
tion is checked. If the assumption is correct, the child-estimated defect will accurately predict the parent-estimated
defect. If the assumption is incorrect, the child-estimated defect will not accurately predict the parent-estimated
defect since the conditional child ensembles neglect the contributions of structures that lack the sandwiching base
pairs. During subsequence merging, if the decomposition assumption is discovered to be incorrect, hierarchical en-
semble redecomposition is performed based on the newly available parental base-pairing information. The details
of subsequence merging, redecomposition, and reoptimization are as follows.
After leaf reoptimization terminates, parent nodes at depth d = D− 1 merge their left and right child sequences
to create the candidate sequence φˆ⇤d . The parental objective function estimate, M˜d, is calculated and the candidate
sequence, φˆ⇤d , is accepted if it decreases M˜d and rejected otherwise. If the parental stop condition
M˜d  max(f stopd ,M˜d+1/fstringent) (S13)
is satisfied, merging continues up to the next level in the forest. Otherwise, failure to satisfy the parental stop
condition indicates the existence of the decomposition defect,
M˜d − M˜d+1/fstringent > 0,
exceeding the basal level permitted by the parameter fstringent. The parent node at depth d whose replacement by
its children results in the greatest underestimate of the objective function at level d is subjected to structure- and
probability-guided hierarchical ensemble decomposition (Section S1.10.2). Additional parents are redecomposed
until
M˜d − M˜⇤d+1/fstringent  fredecomp(M˜d − M˜d+1/fstringent)
where M˜d+1 is the child defect estimate before any redecomposition, M˜⇤d+1 is the child defect estimate after
redecomposition, and fredecomp 2 (0, 1).
After redecomposition, the current sequences at depth d are pushed to level D, the lowest encountered defect
estimate is reset for all levels below d, and a new round of leaf mutation and leaf reoptimization is performed. Fol-
lowing leaf reoptimization, merging begins again. Subsequence merging and reoptimization terminate successfully
if the parental stop condition (S13) is satisfied at depth d = 1. The outcome of subsequence merging, redecomposi-
tion, and reoptimization is the feasible sequence, φ⇤1 , corresponding to the lowest encountered M˜1.
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S1.9 Test Tube Evaluation, Refocusing, and Reoptimization
Using test tube ensemble focusing, initial sequence optimization is performed for the on-target complexes in active,
neglecting the off-target complexes in passive. At the termination of initial forest optimization, the estimated design
objective function is M˜1, calculated using (S8). The estimated contributions for each tube h 2 ⌦ are based on
complex concentration estimates, x˜h, activeh , calculated using deflated total strand concentrations (equation (10) of
Reference 1) to create a built-in defect allowance for the effect of the neglected off-targets in  passiveh . The exact
design objective function,M, is then evaluated for the first time over the full ensemble . For this exact calculation,
the objective function,M, is based on complex concentrations, xh, h , calculated using the full strand concentrations
(equation (9) of Reference 1).
If the objective function satisfies the termination stop condition,
M  max(fstop,M˜1), (S14)
sequence design terminates successfully. Otherwise, failure to satisfy the termination stop condition indicates the
existence of the focusing defect,
M− M˜1 > 0. (S15)
The multistate test tube ensemble is refocused by transferring the highest-concentration off-target in  passive to
 active. Additional off-targets are transferred from  passive to  active until
M− M˜⇤1  frefocus(M− M˜1), (S16)
where M˜1 is the forest-estimated defect before any refocusing, M˜⇤1 is the forest-estimated defect after refocusing
(calculated using deflated total strand concentrations (equation (10) of Reference 1) if  passive 6= ;), and frefocus 2
(0, 1).
The new off-targets in  active are then decomposed using probability-guided hierarchical ensemble decomposi-
tion (Section S1.10.1), the decomposition forest is augmented with new nodes at all depths, and forest reoptimization
commences starting from the final sequences from the previous round of forest optimization. During forest reopti-
mization, the algorithm actively attempts to destabilize the off-targets that were added to active. This process of test
tube ensemble refocusing and forest reoptimization is repeated until the termination stop condition (S14) is satisfied,
which is guaranteed to occur in the event that all off-targets are eventually added to  active. At the conclusion of
sequence design, the algorithm returns the feasible sequence set, φ , that yielded the lowest encountered objective
function,M.
S1.10 Hierarchical Ensemble Decomposition Using Multiple Exclusive Split-Points
Prior to sequence optimization, in the absence of base-pairing probability information, hierarchical ensemble decom-
position is performed for each complex j 2  active based on user-specified target structures. During subsequence
merging, if decomposition defects are encountered, or during test tube evaluation, if focusing defects are encoun-
tered, subsequent hierarchical ensemble decomposition takes advantage of the newly available parental base-pairing
probabilities. In either case, selection of the optimal set of exclusive split-points is determined using a branch and
bound algorithm to minimize the cost of evaluating the child nodes (see Section S1.4 of Reference 1).
S1.10.1 Probability-Guided Decomposition using Multiple Exclusive Split-Points
During redecomposition (Section S1.8) and refocusing (Section S1.9), parent nodes that lack a target structure are
decomposed via probability-guided decomposition using multiple exclusive split-points. See Reference 1 for details
on probability-guided decomposition.
S1.10.2 Structure- and Probability-Guided Decomposition using Multiple Exclusive Split-Points
During redecomposition (Section S1.8), parent nodes that have a target structure are decomposed via structure- and
probability-guided decomposition using multiple exclusive split-points. See Reference 1 for details on structure-
and probability-guided decomposition.
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Table S1. IUPAC degenerate nucleotide codes for RNA.
Code Nucleotides
M A or C
R A or G
W A or U
S C or G
Y C or U
K G or U
V A, C, or G
H A, C, or U
D A, G, or U
B C, G, or U
N A, C, G, or U
T replaces U for DNA.
S1.10.3 Multistate Test Tube Ensemble Defect Estimate Using Multiple Exclusive Decompositions
Because exclusive split-points lead to exclusive structural ensembles, the expressions used to estimate ensemble
properties over ⌦ (Section S1.5) can be generalized to account for the possibility of multiple exclusive split-points
within any parent in the decomposition forest. See Reference 1 for details.
S1.11 Generation of Feasible Sequences
Each time the sequence is initialized, mutated, or reseeded, a feasible sequence is generated by solving a constraint
satisfaction problem based on the user-specified constraints inR.
S1.11.1 Constraint Satisfaction Problem
A constraint satisfaction problem (CSP)58 is specified as:
• a set of variables,
• a set of domains, each listing the possible values for the corresponding variable,
• a set of constraints, each defined by a constraint relation operating on a subset of the variables.
In the present setting, each variable is the sequence, φa, of a nucleotide, a. For RNA, the domain for each variable is
{A,C,G,U}. Each constraint inR is specified using one of the constraint relations in Table 1 applied to one or more
nucleotides (e.g., specification of constraint Rmatcha,b requires that φ
a = φb for nucleotides a and b).
In general, constraint satisfaction problems are NP-complete, so general-purpose polynomial-time algorithms
are unavailable.58 Empirically, we find that CSPs arising in the context of nucleic acid reaction pathway engineering
specified in terms of the diverse constraint relations of Table 1 can typically be solved efficiently using the branch
and propagate algorithm described below.
S1.11.2 Branch and Propagate Algorithm
We solve the CSP using a branch and propagate algorithm that returns a solution if one exists and returns a warning
if no solution exists. Initially, the domain for each variable is {A,C,G,U}. We first pre-process the CSP by trivially
removing any value from the domain of a variable a that is inconsistent with a constraint (e.g., an assignment
or library constraint). We further pre-process the CSP using constraint propagation to impose arc consistency as
described below.
The branch and propagate algorithm involves iterated application of two ingredients:
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• constraint propagation is used to narrow the search space by imposing arc consistency on each pair of vari-
ables: for any value in the domain of variable a there must be a consistent value in the domain of every other
variable b, otherwise that value of variable a is inconsistent and can be removed from the domain of a (see
“Chapter 3: Consistency-Enforcing and Constraint Propagation” of Reference 58).
• depth-first branching is used to extend a candidate partial solution by assigning a consistent value to one
additional variable a, followed by backtracking to reassign the value of the most-recently assigned variable if
no value in the domain of a is consistent with previous assignments (see “Chapter 5: General Search Strategies:
Look-Ahead” of Reference 58).
S1.11.3 Feasible Sequence Inititialization
Sequence initialization (Section S1.7.1) commences with constraint propagation to impose arc consistency and then
a first branching step in which a variable, a, is randomly selected and randomly assigned a value from the domain of
a. Constraint propagation is then used to impose arc consistency and the next branching step is taken by randomly
selecting an unassigned variable, b, and assigning a consistent value from the domain of b. Backtracking is performed
if no consistent value for b exists. The branch and propagate algorithm returns a feasible set of initial sequences,
φ active , if one exists, and a warning otherwise.
S1.11.4 Feasible Sequence Mutation
During leaf mutation (Section S1.7.2), a feasible candidate sequence is generated by mutating the current leaf se-
quence, φ⇤D . This process begins with the sequence design algorithm randomly selecting a nucleotide a for mutation
with probability (S12) and randomly assigning a new value from the domain of a. We then solve a CSP to obtain
a valid candidate sequence consistent with the new value of a. Constraint propagation is used to impose arc con-
sistency with the new value of a and any variables that require reassignment are added to the candidate mutation
set, ⇠a. Initially, branching is performed by randomly selecting an unassigned variable b from ⇠a with probability
proportional to the size of the domain of b (i.e., using weight
wb = |domain(b)| (S17)
to calculate the probability of selecting b). For each value φb in the domain of b, we check the implications of
arc consistency on the size of the candidate mutation set, ⇠a,b, and create a priority queue based on the minimum
increase in |⇠a,b| relative to |⇠a|. Let |⇠a,b1 | denote the minimum increase, |⇠a,b2 | denote the next largest increase, and
so on. Branching is performed by exploring the values of b according to their rank order in this priority queue. If no
consistent value of b exists, backtracking is performed and the selection weight for variable b (S17) is updated using
wb = ✏wb + (1− ✏)(|⇠a,b1 |− |⇠a|). (S18)
where ✏ = 0.5 is a decay constant. The heuristics (S17) and (S18) seek to preferentially select highly constrained
variables early in the branching process to avoid excessive backtracking. The initial weights (S17) assume that each
variable b will imply a mutation set ⇠a,b that increases in size with the size of domain(b), preferentially selecting
variables with larger domains. With (S18), as we explore different variables b in ⇠a, we explicitly calculate the
implied increase in ⇠a,b due to each branching decision, and update the weights to bias future searching toward
selection of b variables that cause the highest minimal increase in the size of the mutation set ⇠a.
The branch and propagate algorithm returns a feasible candidate sequence, φˆ⇤D , if one exists. Otherwise, the
new value of a is invalid and is removed from the domain of a; a new value of a is randomly selected from the
domain of a, and branch and propagate is applied again. If the only valid value of a is the current value, thenmbad
is incremented and the leaf mutation procedure selects a new nucleotide for mutation with probability (S12).
S1.11.5 Feasible Sequence Reseeding
During leaf reoptimization (Section S1.7.3), a feasible candidate reseeded sequence, φˆ⇤D , is generated by intro-
ducing Mreseed feasible sequence mutations to the current leaf sequence, φ⇤D , via Mreseed consecutive calls to the
S12
branch and propagate algorithm of Section S1.11.4 (selecting nucleotide a for mutation without replacement with
probability (S12)).
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S1.12 Pseudocode
OPTIMIZETUBES(⌦, on⌦ , 
o↵
⌦ , , s , y⌦, ,R)
 active, passive   on, o↵
φ active  INITSEQ(s active ,R)
⇤, D  MAKEFOREST(s active)
φ⇤,M˜1  OPTIMIZEFOREST(φ⇤, D)
M EVALUATEDEFECT(φ )
φˆ ,Mˆ φ ,M
while Mˆ > max(fstop,M˜1)
 active, passive  REFOCUSTUBES( active, passive,
{xˆ
h, 
passive
h
})
⇤, D  AUGMENTFOREST(⇤, D, Pˆ active)
φˆ⇤,M˜1  OPTIMIZEFOREST(φˆ⇤, D)
Mˆ EVALUATEDEFECT(φˆ )
if Mˆ <M
φ ,M φˆ ,Mˆ
return φ 
OPTIMIZEFOREST(φ⇤, D)
M˜d  1 8d 2 {1, . . . , D}
βmerge  false
while ¬βmerge
φ⇤D ,M˜D  OPTIMIZELEAVES(φ⇤D , D)
d D − 1
βmerge  true
while d ≥ 1 and βmerge
φˆ⇤d  MERGESEQ(φ⇤d+1)
Mˆd  ESTIMATEDEFECT(φˆ⇤d)
if Mˆd < M˜d
φ⇤d ,M˜d  φˆ⇤d ,Mˆd
if Mˆd > max(f stopd ,M˜d+1/fstringent)
βmerge  false
⇤, D  REDECOMPOSEFOREST(⇤, D, s⇤d , Pˆ⇤d)
φ⇤D  SPLITSEQ(φˆ⇤d)
M˜d0  1 8d0 2 {d+ 1, . . . , D}
d d− 1
return φ⇤1 ,M˜1
OPTIMIZELEAVES(φ⇤D , D)
φ⇤D ,M˜D  MUTATELEAVES(φ⇤D , D)
mreopt  0
while M˜D > f stopD andmreopt < Mreopt
φˆ⇤D  RESEEDSEQ(φ⇤D , {M˜ah,j},R)
φˆ⇤D ,MˆD  MUTATELEAVES(φˆ⇤D , D)
if MˆD < M˜D
φ⇤D ,M˜D  φˆ⇤D ,MˆD
mreopt  0
else
mreopt  mreopt + 1
return φ⇤D , M˜D
MUTATELEAVES(φ⇤D , D)
M˜D  ESTIMATEDEFECT(φ⇤D )
γbad  ;, mbad  0
while M˜D > f stopD andmbad < Mbad
⇠, φˆ⇤D  SAMPLEMUTATION(φ⇤D , {M˜ah,j},R)
if ⇠ 2 γbad
mbad  mbad + 1
else
MˆD  ESTIMATEDEFECT(φˆ⇤D )
if MˆD < M˜D
φ⇤D ,M˜D  φˆ⇤D ,MˆD
γbad  ;, mbad  0
else
γbad  γbad [ ⇠, mbad  mbad + 1
return φ⇤D ,M˜D
ESTIMATEDEFECT(φ⇤d)
Q˜⇤d , P˜⇤d  CONDITIONALNODALPROPERTIES(φ⇤d)
Q˜ active  ESTIMATECOMPLEXPFUNCS(Q˜⇤d)
P˜ active  ESTIMATECOMPLEXPAIRPROBS(P˜⇤d)
for h 2 ⌦
x˜0h, 0
h
 DEFLATEMASSCONSTRAINTS(x0h, 0
h
)
x˜h, active
h
 ESTIMATECOMPLEXCONCS(Q˜ active
h
, x˜0h, 0
h
)
{M˜ah,j} ESTIMATECONTRIBS(P˜ onh , s onh , x˜h, onh , yh, onh )
M˜d  
P
h2⌦
P
j2 on
h
P
1a|j | M˜
a
h,j
return M˜d
Algorithm S1. Pseudocode for constrained multistate test tube ensemble defect optimization. Consider the set of
target test tubes, ⌦, collectively containing the set of complexes  (comprising the sets of on-target complexes  on⌦
and off-target complexes  o↵⌦ ) with target secondary structures s and target concentrations y⌦, . The function call
OPTIMIZETUBES(⌦, on⌦ , 
o↵
⌦ , , s , y⌦, ,R) returns the set of designed sequences, φ , satisfying the sequence constraints
inR.
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S1.13 Default Algorithm Parameters
Default algorithm parameters are shown in Table S2.
Table S2. RNA design: default algorithm parameters for constrained multistate test tube ensemble defect optimization.
Parameter Value
fstop 0.02
fpassive 0.01
Hsplit 2
Nsplit 12
fsplit 0.99
fstringent 0.99
∆Gclamp −25 kcal/mol
Mbad 300
Mreseed 50
Mreopt 3
fredecomp 0.03
frefocus 0.03
For DNA design, Hsplit = 3.
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S2 Engineering Case Studies
S2.1 Reaction Pathways
S2.1.1 Conditional Self-Assembly via Hybridization Chain Reaction (HCR)
A
c*
b*
b
a
A
c*
b*
b
a
b*
a*
X
B
a*
b
b*
c
X·A
c*
b*
b
a
b*
a*
X·A·B
b*
b*
c*
c
b
b
b*
a*
a*
a
X·A·A·B
a*
a
b
b*
c*
c
b*
b
b*
a*
a
b
b*
c*
Step 2
Step 1
Step 3
Step Reaction Function Mechanism
1 X + A! X·A detect target, first A polymeriza-
tion step
toehold/toehold nucleation,
3-way branch migration
2 X·A + B! X·A·B first B polymerization step, re-
generate target sequence
toehold/toehold nucleation,
3-way branch migration
2k+1 X·(A)k·(B)k + A! X·(A)k+1·(B)k generic A polymerization step,
k = 1, 2, . . .
toehold/toehold nucleation,
3-way branch migration
2k+2 X·(A)k+1·(B)k + B! X·(A)k+1·(B)k+1 generic B polymerization step,
k = 1, 2, . . .
toehold/toehold nucleation,
3-way branch migration
Figure S1. Reaction pathway for conditional self-assembly via hybridization chain reaction (HCR).20 Target X triggers self-
assembly of metastable hairpins A and B into a long nicked dsDNA polymer via a chain reaction of alternating A and B
polymerization steps. Top: Reaction pathway schematic. Bottom: Elementary step details.
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S2.1.2 Boolean Logic AND using Toehold Sequestration Gates
Step 1
Step 2
Step 3
a* e* f*
e f
h*
g
A·B
X·A
B·C
Y·D
B
X
Y
e f g
a b
a
a* e* f* h*
b
C·D·E
D·E
E
i
d*
g*
f*
z y
c*
w
x
w
x
y
z
dc
g* f*
g f
e
d*c*
d
i
c
d*
i
z y
c*
w
x
Step Reaction Function Mechanism
1 X + A·B! X·A + B translate X target sequence toehold/toehold nucleation,
3-way branch migration
2 B + C·D·E! B·C + D·E detect translated first target toehold/toehold nucleation,
3-way branch migration, ex-
pose toehold
3 Y + D·E! Y·D + E detect second target toehold/toehold nucleation,
3-way branch migration
Figure S2. Reaction pathway for Boolean logic AND using toehold sequestration gates.59 Gates implement the logical opera-
tion “if targets X AND Y are detected, generate output E”. Top: Reaction pathway schematic. Bottom: Elementary step details.
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S2.1.3 Self-Assembly of a 3-Arm Junction via Catalytic Hairpin Assembly (CHA)
X
Step 1 Step 2
Step 3b Step 3a
A·B·C
X·A
X·A·B
X·A·B·C
A
B
C
Step Reaction Function Mechanism
1 X + A! X·A assemble with catalyst X toehold/toehold nucleation, 3-way
branch migration
2 X·A + B! X·A·B assemble toehold/toehold nucleation, 3-way
branch migration
3a X·A·B + C! X·A·B·C assemble toehold/toehold nucleation, 3-way
branch migration
3b X·A·B·C! X + A·B·C disassemble from catalyst X
and assemble 3-arm junction
intracomplex blunt-end strand in-
vasion, 3-way branch migration
Figure S3. Reaction pathway for self-assembly of a 3-arm junction via catalytic hairpin assembly (CHA).24 Target X catalyzes
self-assembly of metastable hairpins A, B, and C into 3-arm junction A·B·C. Top: Reaction pathway schematic. Bottom: Ele-
mentary step details.
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S2.1.4 Boolean Logic AND using a Cooperative Hybridization Gate
cbB
a
b c
d
a*
b* c*
d*
Y·A·X
a b 
X
c dY
a
b
b* c*
c d*
A·B
Step 1
Step Reaction Function Mechanism
1 X + Y + A·B! Y·A·X + B cooperative detection of X and Y
to generate output B
toehold/toehold nucleation,
3-way branch migration
Figure S4. Reaction pathway for Boolean logic AND using a cooperative hybridization gate.60 Gate implements the logical
operation “if targets X AND Y are detected, cooperatively generate output B”. Top: Reaction pathway schematic. Bottom: El-
ementary step details.
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S2.1.5 Conditional Dicer Substrate Formation via Shape and Sequence Transduction with Small Condi-
tional RNAs (scRNAs)
Step 1
Step 2
C
a b c
a*
y*
z*
b* c*
X·A B·C
B
a
b
c
y
x
z
a
b
y
s
x w
y*
z*
a*
x* w*
x y z a
x*
w*
y* z* a*
b
w
x
y
s
A·B
y
x
z a b
y* z* a* b*
c*X
Step Reaction Function Mechanism
1 X + A·B! X·A + B detect target X (sequence ‘a-b-c’) toehold/toehold nucleation, 3-way branch mi-
gration, spontaneous dissociation
2 B + C! B·C form Dicer substrate targeting independent
target Y (sequence ‘w-x-y-z’)
toehold/loop nucleation, 3-way branch migra-
tion
Figure S5. Reaction pathway for conditional Dicer substrate formation via shape and sequence transduction with small condi-
tional RNAs (scRNAs).33 scRNA A·B detects target X (comprising sequence ‘a-b-c’), generating intermediate B that assembles
with scRNA C to generate Dicer substrate B·C (targeting independent sequence ‘w-x-y-z’ for silencing). Top: Reaction pathway
schematic. Bottom: Elementary step details.
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S2.2 Specification of Target Test Tubes
S2.2.1 General Formulation
Consider specification of the multistate test tube ensemble, ⌦, for the design of N orthogonal systems for a reaction
pathway ofM elementary steps, each corresponding to a self-assembly or disassembly operation in which complexes
form or break. One elementary step tube is specified for each stepm = 0, 1, . . . ,M for each system n = 1, . . . , N
(treating formation of the initial reactants as a precursor “Step 0”). Additionally, a single global crosstalk tube is
specified to minimize off-pathway interactions between the reactive species generated during all elementary steps of
all systems. The total number of target test tubes is then |⌦| = (M + 1)⇥N + 1.
Elementary Step Tubes. Consider elementary stepm for orthogonal system nwith on-pathway products productsmn
that are intended to form at non-zero concentrations at equilibrium, and reactants  reactantsmn that are intended to
fully convert into the on-pathway products at equilibrium. Furthermore, consider the set of off-pathway products,
 crosstalkmn , corresponding to unintended interactions between these same reactants.
The elementary step tube for stepm of system n is then:
Stepmn tube:  onh ⌘  productsmn ,  o↵h ⌘  reactantsmn [ crosstalkmn
where the on-targets are the on-pathway products, and the off-targets are the reactants and off-pathway crosstalk
products. For step m of system n, this tube designs for full conversion of cognate reactants into cognate products
and against local crosstalk between these same reactants. One elementary step tube is specified for each elementary
stepm = 0, 1, . . . ,M for each system n = 1, . . . , N .
The off-pathway crosstalk products for stepm of system n are defined as:
 crosstalkmn =  
LLmax
mn − excludemn
where the set  LLmaxmn denotes the set of all complexes of up to Lmax strands (that are not already on-targets
in the Step mn tube). The set  excludemn contains energetically favorable complexes that we wish to exclude from
the ensemble for the current elementary step (e.g., downstream on-pathway products, or off-pathway products that
are inhibited kinetically rather than thermodynamically, and hence are not suitable for inclusion in the equilibrium
optimization ensemble).
Global Crosstalk Tube. To actively design against global crosstalk, we additionally specify a single global
crosstalk tube:
Global crosstalk tube:  onh ⌘  reactiveglobal ,  o↵h ⌘  crosstalkglobal
where  reactiveglobal denotes the set of all reactive species generated during all elementary steps for all systems and
 crosstalkglobal denotes the set of undesired crosstalk products resulting from interactions between these species.
For the global crosstalk tube, we exploitmotif simplification to enable specification of the on-target and off-target
complexes using using only monomers and dimers. The presumption is that motif complexity will typically decrease
rather than increase crosstalk between reactive species, so that for the global crosstalk tube, motif simplification
is justified in the service of efficiency and simplicity. By contrast, for the elementary step tubes, reactant and
product complexes are treated without motif simplification, ensuring that any energetic effects associated with the
full complexes (either unfavorable [e.g., 3-arm junction for CHA product] or favorable [e.g., nick stack for HCR])
are taken into consideration.
To define various forms of motif simplification, it is helpful to define input and output domains that participate
in the elementary steps. Each scRNA or scDNA motif (monomer, dimer, trimer, etc) has one or more input domains
that control the state of one or more output domains. An inactive output domain is toggled to the active state when
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sequestering input domains hybridize to active output domains generated by earlier elementary steps in the reaction
pathway. Nucleation with an input domain occurs via hybridization to an accessible loop or toehold. Targets that
serve as inputs to a reaction pathway may be viewed as unconditionally active output domains that are available to
hybridize to complementary input domains at any step in a reaction pathway.
Using motif simplification, we specify the reactive species and cognate products for system n as follows:
• λsimplen : scRNA and scDNA motifs with multiple input or output domains are simplified so that only the input
and output domains for a single elementary step are present in each simplified motif.
• λss-outn : single-stranded output domains are specified for each elementary step, removing other concatenated
or hybridized domains that represent the history or future of the reaction (participating in previous or future
elementary steps).
• λss-inn : single-stranded nucleation sites within input domains (toeholds or loops) are specified isolated from the
surrounding domains representing the history or future of the reaction.⇤
• λreactiven ⌘ {λsimple [simp λss-out [simp λss-in}n: the set of reactive species for system n is specified using a
union operator [simp that eliminates redundancies when one monomer species is an accessible subsequence
of another monomer species.
• λcognaten : cognate products expected to form from reactive species in λreactiven based on sequence complemen-
tarity imposed by the reaction pathway (e.g., an input domain within a motif in λsimplen is expected to hybridize
to a complementary output domain in λss-outn ).
These definitions for λreactiven and λ
cognate
n are then used to define the on-targets for the global crosstalk tube:
 reactiveglobal ⌘ [n=1,...,N{λreactiven }
and the off-targets for the global crosstalk tube:
 crosstalkglobal ⌘  LLmaxglobal − [n=1,...,N{λcognaten }
Here,  LLmaxglobal denotes the set of all complexes of up to Lmax strands (that are not already on-targets in the global
crosstalk tube). The set [n=1,...,N{λcognaten } contains all the cognate products that the reactive species in the N
orthogonal systems are expected to form based on sequence complementarity. Crucially, by excluding these cognate
products from  crosstalkglobal , they do not appear in the global crosstalk tube as either on-targets or off-targets. Hence,
all reactive species in the global crosstalk tube are forced to perform either no reaction (remaining as desired on-
targets) or to undergo a crosstalk reaction (forming undesired off-targets), providing the basis for minimization of
global crosstalk during sequence optimization.
⇤The role of λss-inn is to enable  crosstalkglobal (the off-targets for the global crosstalk tube) to be specified without requiring any complexes
larger than dimers. For example, consider a dimer motif with an exposed toehold. Crosstalk via kissing of this toehold with that of another
dimer motif would yield a tetramer off-target; including these toeholds as isolated monomers in λss-inn allows this crosstalk interaction to be
described by an off-target dimer, which is automatically included in  crosstalkglobal by considering all off-targets of up to Lmax = 2 strands.
Further, inclusion of loop nucleation sites in λss-inn enables designing against pseudoknotted toehold/loop and loop/loop crosstalk interactions
without needing to explicitly include pseudoknots in the structural ensemble of any complex.
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S2.2.2 Conditional Self-Assembly via HCR
Target test tubes are defined using the specification of Section S2.2.1 with the following definitions. The total number
of target test tubes is |⌦| =Pn=1,...,N{Step 0, Step 1, Step 2, Step 3}n + Crosstalk = 4N + 1; the target test tubes
in the multistate test tube ensemble, ⌦, are indexed by h = 1, . . . , 4N + 1. Lmax = 2 for all tubes.
Reactants for system n
• Target: Xn
• Hairpins: {A, B}n
Elementary step tubes for system n
• Step 0n tube:  
products
0n
⌘ {X, A, B}n; reactants0n ⌘ {A·B}n (dimer nucleus that inhibits leakage); exclude0n ⌘
{X·A}n (downstream on-pathway product)
• Step 1n tube:  
products
1n
⌘ {X·A}n;  reactants1n ⌘ {X, A}n;  exclude1n ⌘ ;
• Step 2n tube:  
products
2n
⌘ {X·A·B}n;  reactants2n ⌘ {X·A, B}n;  exclude2n ⌘ ;
• Step 3n tube:  
products
3n
⌘ {X·A·A·B}n;  reactants3n ⌘ {X·A·B, A}n;  exclude3n ⌘ ;
Global crosstalk tube
• Crosstalk tube:  reactiveglobal ⌘ [n=1,...,N{λreactiven };  crosstalkglobal ⌘  LLmaxglobal − [n=1,...,N{λcognaten }
The reactive species and cognate products for system n are:
• λsimplen ⌘ {A, B}n
• λss-outn ⌘ {X, Aout, Bout}n
• λss-inn ⌘ {Atoe, Btoe}n
• λreactiven ⌘ {A, B, Aout, Bout}n
• λcognaten ⌘ {Aout·B, Bout·A}n
based on the definitions (listed 50 to 30 using the sequence domain notation of Figure S1):
• A ⌘ Ain-Aout
• Atoe ⌘ a
• Ain ⌘ a-b
• Aout ⌘ c*-b*
• B ⌘ Bout-Bin
• Btoe ⌘ c
• Bin ⌘ b-c
• Bout ⌘ b*-a*
• X ⌘ b*-a*
Note: Xn is identical to Boutn , so it is implicitly included in the definition of λ
reactive
n . To avoid redundancy, the
toeholds of λss-inn are not included in the definition of λ
reactive
n ; these toeholds are already available to form dimer
crosstalk products in the hairpin monomers of λsimplen .
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Step 1n {X·A}n {X, A}n [  LLmax1n
Step 2n {X·A·B}n {X·A, B}n [  LLmax2n
Step 3n {X·A·A·B}n {X·A·B, A}n [  LLmax3n
Crosstalk [n=1,...,N{λreactiven }  LLmaxglobal − [n=1,...,N{λcognaten }
Figure S6. Target test tubes for conditional self-assembly via HCR (reaction pathway of Figure S1). Top: Target test tube
schematics. Bottom: Target test tube details. Each target test tube contains the depicted on-target complexes (each with
the depicted target structure and a target concentration of 10 nM) and the off-target complexes listed in the table (each with
vanishing target concentration). To simultaneously design N orthogonal systems, the total number of target test tubes is
|⌦| = 4N + 1. Lmax = 2 for all tubes. Design conditions: DNA in 1 M Na+ at 25 C.
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S2.2.3 Boolean Logic AND using Toehold Sequestration Gates
Target test tubes are defined using the specification of Section S2.2.1 with the following definitions. The total number
of target test tubes is |⌦| =Pn=1,...,N {Step 0, Step 1, Step 2, Step 3}n + Crosstalk = 4N + 1; the target test tubes
in the multistate test tube ensemble, ⌦, are indexed by h = 1, . . . , 4N + 1. Lmax = 2 for all tubes.
Reactants for system n
• Targets: {X, Y}n
• Translator gate: {A·B}n
• AND gate: {C·D·E}n
Elementary step tubes for system n
• Step 0n:  
products
0n
⌘ {X, Y, A·B, C·D·E}n;  reactants0n ⌘ {A, B, C, D, E, C·D, D·E}n;  exclude0n ⌘ {X·A}n
• Step 1n:  
products
1n
⌘ {X·A, B}n;  reactants1n ⌘ {X, A·B}n;  exclude1n ⌘ ;
• Step 2n:  
products
2n
⌘ {B·C, D·E}n;  reactants2n ⌘ {B, C·D·E}n;  exclude2n ⌘ ;
• Step 3n:  
products
3n
⌘ {Y·D, E}n;  reactants3n ⌘ {Y, D·E}n;  exclude3n ⌘ ;
Global crosstalk tube
• Crosstalk tube:  reactiveglobal ⌘ [n=1,...,N{λreactiven };  crosstalkglobal ⌘  LLmaxglobal − [n=1,...,N{λcognaten }
The reactive species and cognate products for system n are:
• λsimplen ⌘ {A·B, C·Dout, D·E}n
• λss-outn ⌘{X, Y, B, Dout, E}n
• λss-inn ⌘ {Atoe, Ctoe, Dtoe}n
• λreactiven ⌘ {A·B, C·Dout, D·E, X, Y, B, Dout, E, Atoe, Ctoe}n
• λcognaten ⌘ {X·A, B·C, Y·D, X·Atoe, B·Ctoe}n
based on the definitions (listed 50 to 30 using the sequence domain notation of Figure S2):
• A ⌘ h*-f*-e*-a*
• Atoe ⌘ a*
• B ⌘ e-f-g
• C ⌘ g*-f*
• Ctoe ⌘ f*
• D ⌘ Dout-Din
• Dtoe ⌘ d*
• Din ⌘ c*
• Dout ⌘ i-d*
• E ⌘ w-x-y-z
• X ⌘ a-b
• Y ⌘ c-d
Note: Dtoen is contained in D
out
n , providing a toehold adjacent to D
in
n . To avoid redundancy, we omit D
toe
n from
λreactiven because it is a subsequence of D
out
n in λ
ss-out
n .
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Figure S7. Target test tubes for Boolean logic AND using toehold sequestration gates (reaction pathway of Figure S2). Top: Tar-
get test tube schematics. Bottom: Target test tube details. Each target test tube contains the depicted on-target complexes (each
with the depicted target structure and a target concentration of 10 nM) and the off-target complexes listed in the table (each
with vanishing target concentration). To simultaneously design N orthogonal systems, the total number of target test tubes is
|⌦| = 4N + 1. Lmax = 2 for all tubes. Design conditions: DNA in 1 M Na+ at 25 C.
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S2.2.4 Self-Assembly of a 3-Arm Junction via CHA
Target test tubes are defined using the specification of Section S2.2.1 with the following definitions. The total number
of target test tubes is |⌦| =Pn=1,...,N {Step 0, Step 1, Step 2, Step 3a, Step 3b}n + Crosstalk = 5N + 1; the target
test tubes in the multistate test tube ensemble, ⌦, are indexed by h = 1, . . . , 5N + 1. Lmax = 2 for all tubes.
Reactants for system n
• Target: Xn
• Hairpins: {A, B, C}n
Elementary step tubes for system n
• Step 0n:  
products
0n
⌘ {X, A, B, C}n;  reactants0n ⌘ ;;  exclude0n ⌘ {X·A}n
• Step 1n:  
products
1n
⌘ {X·A}n;  reactants1n ⌘ {X, A}n;  exclude1n ⌘ ;
• Step 2n:  
products
2n
⌘ {X·A·B}n;  reactants2n ⌘ {X·A, B}n;  exclude2n ⌘ ;
• Step 3an:  
products
3an ⌘ {X·A·B·C}n;  reactants3an ⌘ {X·A·B, C}n;  exclude3an ⌘ ;
• Step 3bn:  
products
3bn ⌘ {X, A·B·C}n;  reactants3bn ⌘ {X·A·B·C}n;  exclude3bn ⌘ ;
Note: Step 3 combining an assembly operation (Step 3a; addition of C) with a disassembly operation (Step 3b;
removal of X) is described using two target test tubes; the Step 3a tube prevents completion of the full operation by
excluding the final product A·B·C from the ensemble (Lmax = 2 includes all off-targets up to dimers).
Crosstalk tube
• Crosstalk tube:  reactiveglobal ⌘ [n=1,...,N{λreactiven };  crosstalkglobal ⌘  LLmaxglobal − [n=1,...,N{λcognaten }
The reactive species and cognate products for system n are:
• λsimplen ⌘ {A, B, C}n
• λss-outn ⌘ {X, Aout, Bout, Cout}n
• λss-inn ⌘ {Atoe, Btoe, Ctoe}n
• λreactiven ⌘ {A, B, C, X, Aout, Bout, Cout}n
• λcognaten ⌘ {X·A, Aout·B, Bout·C, Cout·A, Cout·B, Bout·A, Aout·C}n
based on the definitions (listed 50 to 30 using the sequence domain notation of Figure S3):
• A ⌘ Ain-Aout
• Atoe ⌘ a
• Ain ⌘ a-x-b-y
• Aout ⌘ z*-c*-y*-b*-x*
• B ⌘ Bin-Bout
• Btoe ⌘ b
• Bin ⌘ b-y-c-z
• Bout ⌘ x*-a*-z*-c*-y*
• C ⌘ Cin-Cout
• Ctoe ⌘ c
• Cin ⌘ c-z-a-x
• Cout ⌘ y*-b*-x*-a*-z*
• X ⌘ y*-b*-x*-a*
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Figure S8. Target test tubes for self-assembly of a 3-arm junction via CHA (reaction pathway of Figure S3). Top: Target
test tube schematics. Bottom: Target test tube details. Each target test tube contains the depicted on-target complexes (each
with the depicted target structure and a target concentration of 10 nM) and the off-target complexes listed in the table (each
with vanishing target concentration). To simultaneously design N orthogonal systems, the total number of target test tubes is
|⌦| = 5N + 1. Lmax = 2 for all tubes. Design conditions: DNA in 1 M Na+ at 25 C.
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S2.2.5 Boolean Logic AND using a Cooperative Hybridization Gate
Target test tubes are defined using the specification of Section S2.2.1 with the following definitions. The total number
of target test tubes is |⌦| =Pn=1,...,N {Step 0, Step 1}n + Crosstalk = 2N +1; the target test tubes in the multistate
test tube ensemble, ⌦, are indexed by h = 1, . . . , 2N + 1. Lmax = 2 for all tubes.
Reactants for system n
• Targets: {X, Y}n
• Cooperative gate: {A·B}n
Elementary step tubes for system n
• Step 0n:  
products
0n
⌘ {X, Y, A·B}n;  reactants0n ⌘ {A·X·B, A·Y·B}n;  exclude0n ⌘ ;
• Step 1n:  
products
1n
⌘ {Y·A·X, B}n;  reactants1n ⌘ {X, Y, A·B}n;  exclude1n ⌘ ;
Note: Individual targets do not appreciably bind the cooperative gate. In the Step 0n tube, the reactants are prevented
from generating the product Y·A·X, because this trimer is excluded from the test tube ensemble (Lmax = 2 includes
all off-targets up to dimers).
Crosstalk tube
• Crosstalk tube:  reactiveglobal ⌘ [n=1,...,N{λreactiven };  crosstalkglobal ⌘  LLmaxglobal − [n=1,...,N{λcognaten }
The reactive species and cognate products for system n are:
• λsimplen ⌘ {Aleft·Bleft, Aright·Bright}n
• λss-outn ⌘ {X, Y, B}n
• λss-inn ⌘ {Aleft-toe, Aright-toe}n
• λreactiven ⌘ {Aleft·Bleft, Aright·Bright, X, Y, B, Aleft-toe, Aright-toe}n
• λcognaten ⌘ {X·Aleft, Y·Aright, X·Aleft-toe, Y·Aright-toe, Aleft·B, Aright·B}n
based on the definitions (listed 50 to 30 using the sequence domain notation of Figure S4):
• A ⌘ Aright-Aleft
• Aleft-toe ⌘ a*
• Aleft ⌘ b*-a*
• Aright-toe ⌘ d*
• Aright ⌘ d*-c*
• B ⌘ Bleft-Bright
• Bleft ⌘ b
• Bright ⌘ c
• X ⌘ a-b
• Y ⌘ c-d
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Figure S9. Target test tubes for Boolean logic AND using a cooperative hybridization gate (reaction pathway of Figure S4).
Top: Target test tube schematics. Bottom: Target test tube details. Each target test tube contains the depicted on-target com-
plexes (each with the depicted target structure and a target concentration of 10 nM) and the off-target complexes listed in the
table (each with vanishing target concentration). To simultaneously design N orthogonal systems, the total number of target
test tubes is |⌦| = 2N + 1. Lmax = 2 for all tubes. Design conditions: DNA in 1 M Na+ at 25 C.
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S2.2.6 Conditional Dicer Substrate Formation via Shape and Sequence Transduction with scRNAs
Target test tubes are defined using the specification of Section S2.2.1 with the following definitions. The total number
of target test tubes is |⌦| = Pn=1,...,N {Step 0, Step 1, Step 2}n + Crosstalk = 3N + 1; the target test tubes in the
multistate test tube ensemble, ⌦, are indexed by h = 1, . . . , 3N + 1. Lmax = 2 for all tubes.
Reactants for system n
• Target: Xn
• scRNAs: {A·B, C}n
Elementary step tubes for system n
• Step 0n:  
products
0n
⌘ {X, A·B, C}n;  reactants0n ⌘ {A, B·C}n;  exclude0n ⌘ {X·A}
• Step 1n:  
products
1n
⌘ {X·A, B}n;  reactants1n ⌘ {X, A·B}n;  exclude1n ⌘ ;
• Step 2n:  
products
2n
⌘ {B·C}n;  reactants2n ⌘ {B, C}n;  exclude2n ⌘ ;
Crosstalk tube
• Crosstalk tube:  reactiveglobal ⌘ [n=1,...,N{λreactiven };  crosstalkglobal ⌘  LLmaxglobal − [n=1,...,N{λcognaten }
The reactive species and cognate products for system n are:
• λsimplen = {A·B, C}n
• λss-outn = {X, B, Cout}n
• λss-inn = {Atoe, Cloop}n
• λreactiven = {A·B, C, X, B, Cout, Atoe, Cloop}n
• λcognaten = {X·A, B·C, X·Atoe, B·Cloop}n
based on the definitions (listed 50 to 30 using the sequence domain notation of Figure S5):
• A ⌘ c*-b*-a*-z*-y*
• Atoe ⌘ c*
• B ⌘ x-y-z-a-b
• C ⌘ Cout-Cin
• Cloop ⌘ s-a*-z*
• Cin ⌘ a*-z*-y*-x*-w*
• Cout ⌘ w-x-y-s
• X ⌘ a-b-c
Note: Cloopn includes portions of both Cinn and C
out
n . Including C
loop
n in λreactiven is not redundant with inclusion of Cn
because pairing to the loop would cause a pseudoknot and hence will not be checked by the ensemble except if the
interaction opens the hairpin. We want to be able to check nucleation with the loop even when the hairpin remains
closed, so we include Cloopn in λreactiven .
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Figure S10. Target test tubes for conditional Dicer substrate formation via shape and sequence transduction with scRNAs
(reaction pathway of Figure S5). Top: Target test tube schematics. Bottom: Target test tube details. Each target test tube
contains the depicted on-target complexes (each with the depicted target structure and a target concentration of 10 nM) and
the off-target complexes listed in the table (each with vanishing target concentration). To simultaneously design N orthogonal
systems, the total number of target test tubes is |⌦| = 3N + 1. Lmax = 2 for all tubes. Design conditions: RNA in 1 M Na+ at
37 C.
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S2.3 Algorithm Performance
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Figure S11. Algorithm performance for design of 1, 2, 4, or 8 orthogonal systems based on the target test tubes of Section S2.2.
Left: Design quality. The stop condition is depicted as a dashed black line. Middle: Design cost. Right: Cost of sequence
design relative to a single evaluation of the objective function. (a) Conditional self-assembly via HCR. (b) Boolean logic AND
using toehold sequestration gates. (c) Self-assembly of 3-arm junction via CHA. (d) Boolean logic AND using a cooperative
hybridization gate. (e) Conditional Dicer substrate formation via shape and sequence transduction with scRNAs.
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Figure S12. Reduced design cost and quality using fstop = 0.05 (dotted lines) instead of fstop = 0.02 (solid lines) for design of
1 or 8 orthogonal systems based on the target test tubes of Section S2.2. Left: Design quality. The stop conditions are depicted
as dashed black lines. Middle: Design cost. Right: Cost of sequence design relative to a single evaluation of the objective
function. (a) Conditional self-assembly via HCR. (b) Boolean logic AND using toehold sequestration gates. (c) Self-assembly
of 3-arm junction via CHA. (d) Boolean logic AND using a cooperative hybridization gate. (e) Conditional Dicer substrate
formation via shape and sequence transduction with scRNAs.
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S2.4 Residual Defects
For each case study, the residual defect plots that follow display for each target test tube h 2 ⌦:
• The structural defect and concentration defect contributions of each on-target complex to the test tube ensem-
ble defect, Mh. The fact that bars are not depicted for off-targets does not mean that the defects associated
with off-targets are neglected. By conservation of mass, nonzero off-target concentrations imply deficien-
cies in on-target concentrations, and these on-target concentration defects are depicted in the bar graphs and
incorporated inMh via (1) and (5).
• The total structural defect and total concentration defect contributions of the tube to the multistate test tube
ensemble defect,M.
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S2.4.1 Conditional Self-Assembly via HCR
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Figure S13. Residual defects for conditional self-assembly via HCR (N = 4 orthogonal systems for target test tubes of
Figure S6). Each panel corresponds to a different tube h 2 {1, . . . , 4N + 1}. For each tube h, the structural defect and
concentration defect contributions to the tube ensemble defect, Mh, are depicted for each complex (pale shaded bars). The
total structural defect and total concentration defect contributions to the multistate test tube ensemble defect, M, are also
depicted for each tube (dark shaded bars). Each bar represents the mean over 30 independent design trials with stop condition
M  0.02. All nucleotide, complex, and tube weights are left at the default value of 1 except for the global crosstalk tube
which is assigned a weight of N to prevent the effect of crosstalk from being diluted in the design objective function as the
number of orthogonal systems increases.
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S2.4.2 Boolean Logic AND using Toehold Sequestration Gates
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Figure S14. Residual defects for Boolean logic AND using toehold sequestration gates (N = 4 orthogonal systems for target
test tubes of Figure S7). Each panel corresponds to a different tube h 2 {1, . . . , 4N +1}. For each tube h, the structural defect
and concentration defect contributions to the tube ensemble defect, Mh, are depicted for each complex (pale shaded bars).
The total structural defect and total concentration defect contributions to the multistate test tube ensemble defect,M, are also
depicted for each tube (dark shaded bars). Each bar represents the mean over 30 independent design trials with stop condition
M  0.02. All nucleotide, complex, and tube weights are left at the default value of 1 except for the global crosstalk tube
which is assigned a weight of N to prevent the effect of crosstalk from being diluted in the design objective function as the
number of orthogonal systems increases.
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S2.4.3 Self-Assembly of a 3-Arm Junction via CHA
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Figure S15. Residual defects for self-assembly of a 3-arm junction via CHA (N = 4 orthogonal systems for target test tubes
of Figure S8). Each panel corresponds to a different tube h 2 {1, . . . , 5N + 1}. For each tube h, the structural defect and
concentration defect contributions to the tube ensemble defect,Mh, are depicted for each complex (pale shaded bars). The total
structural defect and total concentration defect contributions to the multistate test tube ensemble defect, M, are also depicted
for each tube (dark shaded bars). Each bar represents the mean over 30 independent design trials with stop conditionM  0.02.
All nucleotide, complex, and tube weights are left at the default value of 1 except for the global crosstalk tube which is assigned
a weight ofN to prevent the effect of crosstalk from being diluted in the design objective function as the number of orthogonal
systems increases.
S38
S2.4.4 Boolean Logic AND using a Cooperative Hybridization Gate
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Figure S16. Residual defects for Boolean logic AND using a cooperative hybridization gate (N = 4 orthogonal systems for
target test tubes of Figure S9). Each panel corresponds to a different tube h 2 {1, . . . , 2N + 1}. For each tube h, the structural
defect and concentration defect contributions to the tube ensemble defect, Mh, are depicted for each complex (pale shaded
bars). The total structural defect and total concentration defect contributions to the multistate test tube ensemble defect, M,
are also depicted for each tube (dark shaded bars). Each bar represents the mean over 30 independent design trials with stop
conditionM  0.02. All nucleotide, complex, and tube weights are left at the default value of 1 except for the global crosstalk
tube which is assigned a weight of N to prevent the effect of crosstalk from being diluted in the design objective function as
the number of orthogonal systems increases.
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S2.4.5 Conditional Dicer Substrate Formation via Shape and Sequence Transduction with scRNAs
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Figure S17. Residual defects for conditional Dicer substrate formation via shape and sequence transduction with scRNAs
(N = 4 orthogonal systems for target test tubes of Figure S10). Each panel corresponds to a different tube h 2 {1, . . . , 3N+1}.
For each tube h, the structural defect and concentration defect contributions to the tube ensemble defect,Mh, are depicted for
each complex (pale shaded bars). The total structural defect and total concentration defect contributions to the multistate test
tube ensemble defect,M, are also depicted for each tube (dark shaded bars). Each bar represents the mean over 30 independent
design trials with stop conditionM  0.02. All nucleotide, complex, and tube weights are left at the default value of 1 except
for the global crosstalk tube which is assigned a weight of N to prevent the effect of crosstalk from being diluted in the design
objective function as the number of orthogonal systems increases.
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S2.5 Importance of Negative Design in Reducing Crosstalk
10−2 10−1 100
Ensemble defect (M)
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
of
 tr
ial
s
stop condition
a
Design quality
100 101 102 103 104 105 106
Costdes (s)
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
of
 tr
ial
s
Design cost
10−2 10−1 100
Ensemble defect (M)
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
of
 tr
ial
s
stop condition
b
Design quality
100 101 102 103 104 105 106
Costdes (s)
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
of
 tr
ial
s
Design cost
10−2 10−1 100
Ensemble defect (M)
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
of
 tr
ial
s
stop condition
c
Design quality
100 101 102 103 104 105 106
Costdes (s)
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
of
 tr
ial
s
Design cost
10−2 10−1 100
Ensemble defect (M)
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
of
 tr
ial
s
stop condition
d
Design quality
100 101 102 103 104 105 106
Costdes (s)
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
of
 tr
ial
s
Design cost
10−2 10−1 100
Ensemble defect (M)
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
of
 tr
ial
s
stop condition
e
Design quality
100 101 102 103 104 105 106
Costdes (s)
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
of
 tr
ial
s
Design cost
Conditional self-assembly via HCR
Boolean logic AND using toehold sequestration gates
Self-assembly of 3-arm junction via CHA
Boolean logic AND using a cooperative hybridization gate
Conditional Dicer substrate formation via shape and sequence transduction with scRNAs
Off-targets
With
Without
Figure S18. Importance of negative design in reducing crosstalk (N = 8 orthogonal systems). Comparison of designs per-
formed with or without off-targets in the design ensemble. Left: Design quality evaluated by calculating the multistate test
tube ensemble defect (M) over the ensemble containing off-targets. The stop condition is depicted as a dashed black line.
Right: Design cost. (a) Conditional self-assembly via HCR. (b) Boolean logic AND using toehold sequestration gates. (c)
Self-assembly of 3-arm junction via CHA. (d) Boolean logic AND using a cooperative hybridization gate. (e) Conditional
Dicer substrate formation via shape and sequence transduction with scRNAs.
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S2.6 Effect of Sequence Constraints
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Figure S19. Algorithm performance including explicit sequence constraints (N = 1 system). Default: implicit sequence
constraints inherent to the reaction pathway (these constraints are also present in the other cases that follow). Composition
constraint: fraction of S 2 [0.45, 0.55]. Pattern constraint: prevent {AAAA, CCCC, GGGG, UUUU, KKKKKK, MMMMMM, RRRRRR,
SSSSSS, WWWWWW, YYYYYY}. Window constraints: targets X and Y constrained to be subsequences of two different mRNAs
(i.e., biological sequence constraints; see Section S2.6.1). All: all of the above constraints. Left: Design quality. The stop
condition is depicted as a dashed black line. Middle: Design cost. Right: Cost of sequence design relative to a single evaluation
of the objective function. (a) Conditional self-assembly via HCR. (b) Boolean logic AND using toehold sequestration gates.
(c) Self-assembly of 3-arm junction via CHA. (d) Boolean logic AND using a cooperative hybridization gate. (e) Conditional
Dicer substrate formation via shape and sequence transduction with scRNAs. Note: for panel (c) with “All constraints”, only 1
out of 30 independent design trials terminates within the depicted time frame.
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S2.6.1 mRNA Sequences used for Window Constraints
The window constraints used for the studies of Figures 5 and S19 constrain targets X and Y to be subsequences of
zebrafish mRNA sequences tpm3 (2175 nt) and desma (1798 nt), respectively. Zebrafish mRNA sequences were
obtained from the National Center for Biotechnology Information (NCBI).61 Sequences are listed below 50 to 30.
Table S3 lists the sequence domains constrained by window constraints for each reaction pathway, the number of
candidate windows within each mRNA, and the number of these candidate windows that also satisfy the composition
constraints, the pattern prevention constraints, or both the composition and pattern prevention constraints.
mRNA: tropomyosin 3 (tpm3)
Sequence: gAACACUAUUAgCUAUUUgUAgUACUCUAAAgAggACUgCAgAACgCAUCgCAgUAgUggUgAAAAgCCgUgCgUgCgCgUgAAACAUCUgAUCC
UCACgUUACUUCCACUCgCUCUgCgUUUgACUUgUUggCggggCgUUggUgCCUUggACUUUUUUUUCCUCCUUCUCUUCUUCgCggCUCggUCCACUACgCUgC
UCgAgAggAAUCUgCUUUAUUCgACCACACUACUCCUAAAgUAACACAUUAAAAUggCCggAUCAAACAgCAUCgAUgCAgUUAAgAgAAAAAUCAAAgUUUUAC
AACAgCAAgCAgAUgAggCAgAAgAAAgAgCCgAgAUUUUgCAgAgACAggUCgAggAggAgAAgCgUgCCAgggAgCAggCUgAggCAgAggUggCUUCUCUgA
ACAggCgUAUCCAgCUggUUgAggAggAgUUggAUCgUgCUCAggAgAgACUggCCACAgCCCUgCAAAAgCUggAggAAgCCgAgAAggCCgCAgAUgAgAgCg
AgAgAgggAUgAAggUgAUUgAgAACAgggCUCUgAAggAUgAggAgAAgAUggAgCUgCAggAgAUCCAgCUUAAggAggCCAAgCACAUUgCUgAggAggCUg
ACCgCAAAUAUgAAgAggUggCUCgUAAgCUggUgAUCgUUgAgggAgAgUUggAgCgUACAgAggAgAgAgCAgAgCUUgCAgAgAgCCAUgUCAAgCAgAUgg
AggAggAgCUgAgAgCUCUUgACCAgACACUgAAgACUCUUCAggCCUCAgAggAgAAgUAUUCCCAgAAggAggACAAgUAUgAggAAgAAAUCAAgAUCCUCA
CUgAUAAgCUgAAggAggCUgAgACCCgUgCAgAgUUUgCUgAgAggUCUgUggCCAAACUggAgAAAACCAUUgAUgAUUUggAAgAgAAACUgAgAgAUgCUA
AAgAggAgAACAUCAAgAUCCAUgCUACUUUggACCAgACCCUgAgCgAgCUCAAUAgUUUCUAAAgAAgACCUggAgCAgAAAAAAggCCUUUUCUUCCCUUCU
UgACUCCCUCAUCUCAUUUUggUUUCUUUgUCUCUgCACAUCUgAUUCUCCCCCUUUUUUUUUCUUCUCUUCUUCUgCUggAggAUAAgCUCACCAAgCCAACCA
gCAAAAAUgUggUgCCUCUCAAUUUUUCCAAACUACUAUUCCAAgUgAUUUgAgAAAUgAUCUACUACgAUACUCCUCAAgAgUCAAAUgUUgACCUCggggAgC
CUUUUUUggUAUUgCUCCAUgAUCAgAgCUUUACgAgCUAgUgUUUUUUCUgCAUAUCAgCCCAAACUCUCAAUgAUAAUUUUACUggAggCUgAUUUUUgUAAA
AUUUUgUgCCAUAAAAgCCUUgUUggCUUgUCUCUUgCUUggCUUUAgAUCAUUCUCAAgCCAUUUUUUUCCUgCUgUUgCUCUgACACAggUUgUUUUUgCUgg
UCUUgUUggUgCCUgAUCCACUgCUAUCCUUUUCACACCUCUUUUUUUUUUUUCUUCAUCCUgCACAAgUUUCUgCUgCCUgUUAgUCggCAUCACCggUUUUgg
gACCAAAACCACAUCAUgUggUCUgUAACAgUAUgCACAACCAUgCCgUgAggACCAAAUUUgUUUUAUUAUUgUUAUUAUUAUUAAAAgCCUUUgCUUCCAUUC
ggAgUUUgUUUUUUUgAgUAAUAUAUgUAUUCAUUgUUUgggUCgAAUCCCCUUgCUUUUUUAACACAAAUgUUUUgCAAACCACUAUUUgAAAUggUgCACUgU
UAUgggCUUAUggUgAgCAgAUgAggCCAAgUCAUggUUUCUUCAUUAUAAUUUUCUUUUCAUUUgCUUUAAAgAgCCAUAUUCUACCCAgggAAgAAAggUUgA
AgUUgUUUUgUUUUUUUACCgUgAgUUCAAAgCAgUggCACUgCCAgAUUUAAAAggUUCAAAAgCCgUgCAgAUCUAAAAUAUgUAUUAUgAACACAgUAAUgg
gAgCgAAUUgUAACACUUAAUAgUAUACAAAUUUAAgAAACAggggUgAACACAUAgUUUUAACUggAAAAAgCCCACAAUgAUgUgUAAUCACUUUgUUACUgU
CUgUAUCUUgUgUAAUgAUACCUAAAUUCUUUUUUUAAAUAAAAACCAUgAUUUUUACUgUCACUgAAAAAAAAAAAAAAAAAAA
mRNA: desmin a (desma)
Sequence: CAUUUACACAgCgUACAAACCCAACAggCCCAgUCAUgAgCACgAAAUAUUCAgCCUCCgCCgAgUCggCgUCCUCUUACCgCCgCACCUUUggC
UCAggUUUgggCUCCUCUAUUUUCgCCggCCACggUUCCUCAggUUCCUCUggCUCCUCAAgACUgACCUCCAgAgUUUACgAggUgACCAAgAgCUCCgCUUCU
CCCCAUUUUUCCAgCCACCgUgCgUCCggCUCUUUCggAggUggCUCggUggUCCgUUCCUACgCUggCCUUggUgAgAAgCUggAUUUCAAUCUggCUgAUgCC
AUAAACCAggACUUCCUCAACACgCgUACUAAUgAgAAggCCgAgCUCCAgCACCUCAAUgACCgCUUCgCCAgCUACAUCgAgAAggUgCgCUUCCUCgAgCAg
CAgAACUCUgCCCUgACggUggAgAUUgAgCgUCUgCggggUCgCgAgCCCACCCgUAUUgCAgAgCUgUACgAggAggAgAUgAgAgAgCUgCgCggACAggUg
gAggCACUgACCAAUCAgAgAUCCCgUgUggAgAUCgAgAgggACAACCUAgUCgAUgACCUACAgAAACUAAAgCUCAgACUUCAAgAggAgAUCCACCAgAAA
gAggAAgCUgAAAACAACCUUUCUgCUUUCAgAgCUgAUgUCgAUgCUgCCACUCUggCCAggCUggACCUggAAAgACgUAUCgAgggUCUUCACgAAgAgAUU
gCAUUCCUCAggAAgAUUCAUgAggAggAgAUCCgUgAgCUgCAgAACCAgAUgCAggAgAgUCAggUgCAgAUCCAAAUggACAUgUCCAAACCAgACCUgACU
gCggCCCUCAgAgACAUUCgCCUgCAgUACgAggCUAUCgCUgCCAAgAAUAUCAgCgAggCCgAggACUggUAUAAgUCUAAggUUUCAgAUUUgAACCAggCA
gUgAACAAgAAUAACgAggCUCUCAgAgAAgCCAAgCAggAgACCAUgCAgUUCCgUCACCAgCUCCAgUCCUACACCUgCgAgAUUgACUCUCUCAAgggCACC
AAUgAgUCUCUgAggAggCAAAUgAgUgAgAUggAggAgCggCUgggACgUgAggCCggUggUUAUCAggACACUAUCgCCCgUCUCgAggCUgAgAUCgCAAAA
AUgAAAgACgAgAUggCCCgCCACCUCCgCgAgUACCAggAUCUgCUgAAUgUgAAgAUggCUCUggAUgUggAgAUCgCCACCUACAggAAgCUUUUggAAggA
gAggAgAgCAggAUCUCgCUgCCCgUgCAgUCCUUUUCAUCCCUgAgUUUCAgAgAgAgCAgUCCAgAgCAgCACCACCACCAgCAgCAgCAACCACAACgCUCA
UCUgAAgUCCACUCCAAgAAAACAgUCCUgAUCAAgACCAUCgAgACCCgCgAUggCgAggUCgUCAgCgAgUCCACACAgCACCAgCAggACgUCAUgUAAAgC
UUgAgAAACAgAUCgAgUUUCACAgAAUgCCUUgCAUUUUCACUgAUggCCUCAggCUUUUUUAAgCACACACCCAgUAUUgCCgUgACCCAUUACCgCAUgUgg
AUgACgCAUggAgACAAAAggAAAgUgAgCUgAAAAACCAgAgggAggAAAAgUggAAUggUgUgAUgCUgAgCgUUCAgAAAgUggCCAgAUgAgCUCAgAgUU
UCUgAUUUAAUgAAUgUAUgUgUgCgUgUgUgUgUggUUgggUCAUAUCUgAgACACUgUUCCACAgCAACAAAAACAAUAAAAUUCACUgUAUUUUCUCCUAAA
AAAAAAAAAAAAAAAAAAAAAAA
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S2.7 Robustness of Predictions to Model Perturbations
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Figure S20. Robustness of design quality predictions to perturbations in model parameters (N = 8 orthogonal systems). For
each design trial, the median multistate test tube ensemble defect was calculated over 100 perturbed physical models (each
parameter perturbed by Gaussian noise with a standard deviation of 0, 1, 3, 10, or 30% of the parameter modulus). The stop
condition is depicted as a dashed black line. (a) Conditional self-assembly via HCR. (b) Boolean logic AND using toehold
sequestration gates. (c) Self-assembly of 3-arm junction via CHA. (d) Boolean logic AND using a cooperative hybridization
gate. (e) Conditional Dicer substrate formation via shape and sequence transduction with scRNAs.
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S3 Additional Design Studies
Here, we compare the performance of the current constrained multistate test tube design algorithm to that of the
previously published test tube design algorithm1 on the subsidiary design problems of test tube design and complex
design (see Table 3 for a comparison of the design ensembles).
S3.1 Performance for Test Tube Design
Test tube design is a special case of multistate test tube design in which the design ensemble contains only one
target test tube containing an arbitrary number of on-target and off-target complexes (Table 3). For test tube design
comparisons, we use the engineered test set and random test set of target test tubes provided with Reference 1.
For the engineered test set, each on-target structure was randomly generated with stem and loop sizes randomly
selected from a distribution of sizes representative of the nucleic acid engineering literature. For the random test
set, each on-target structure was generated by calculating the minimum free energy structure of a different random
RNA sequence in 1 M Na+ at 37 ◦C. Within each target test tube, there are two on-target dimers (each with a target
concentration of 1 µM) and a total of 106 off-target monomers, dimers, trimers and tetramers (each with vanishing
target concentration), representing all complexes of up to Lmax = 4 strands (excluding the two on-target dimers).
For each test set, 50 target test tubes were generated for each on-target dimer size, {50, 100, 200, 400} nt, with all
strands the same length in each target test tube. The structural properties of the on-target structures in the engineered
and random test sets are summarized in Supplementary Section S3 of Reference 1. Five design trials were run
for each test case using stop condition fstop = 0.01 (i.e., no more than 1% of nucleotides incorrectly paired at
equilibrium). For test tube design, Figures S21 and S22 demonstrate that the performance of the current algorithm
and the previously published test tube design algorithm1 is similar on the engineered and random test sets.
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Figure S21. Algorithm performance for test tube design on the engineered test set. Comparison of the current multistate test
tube design algorithm (solid lines) to the previously published test tube design algorithm1 (dotted lines). (a) Design quality.
The stop condition is depicted as a dashed black line. (b) Design cost. (c) Cost of sequence design relative to a single evaluation
of the objective function. Design conditions: RNA in 1 M Na+ at 37 C.
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Figure S22. Algorithm performance for test tube design on the random test set. Comparison of the current multistate test tube
design algorithm (solid lines) to the previously published test tube design algorithm1 (dotted lines). (a) Design quality. The
stop condition is depicted as a dashed black line. (b) Design cost. (c) Cost of sequence design relative to a single evaluation of
the objective function. Design conditions: RNA in 1 M Na+ at 37 C.
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S3.2 Performance for Complex Design
Complex design is a special case of multistate test tube design in which the design ensemble contains one target
test tube containing one on-target complex and no off-target complexes (Table 3). For complex design comparisons,
we use the (dimer) on-target structures from the target test tubes in the engineered and random test sets described
above. Hence, for the studies, each target test tube contains a single on-target dimer and no off-targets; there are
50 on-target structures of each size {50, 100, 200, 400} nt (using the first-listed on-target dimer in each of the 50
target test tubes of Section S3.1). Five design trials were run for each test case using stop condition fstop = 0.01
(i.e., no more than 1% of nucleotides incorrectly paired at equilibrium). For complex design, Figures S23 and S24
demonstrate that the performance of the current algorithm and the previously published test tube design algorithm1
is similar for the on-target structures in the engineered and random test sets.
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Figure S23. Algorithm performance for complex design using on-target structures from the engineered test set. Comparison
of the current multistate test tube design algorithm (solid lines) to the previously published test tube design algorithm1 (dotted
lines). (a) Design quality. The stop condition is depicted as a dashed black line. (b) Design cost. (c) Cost of sequence design
relative to a single evaluation of the objective function. The optimality bound4 is depicted as a dashed black line. Design
conditions: RNA in 1 M Na+ at 37 C.
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Figure S24. Algorithm performance for complex design using on-target structures from the random test set. Comparison of
the current multistate test tube design algorithm (solid lines) to the previously published test tube design algorithm1 (dotted
lines). (a) Design quality. The stop condition is depicted as a dashed line. (b) Design cost. (c) Cost of sequence design relative
to a single evaluation of the objective function. The optimality bound4 is depicted as a dashed black line. Design conditions:
RNA in 1 M Na+ at 37 C.
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